NCT06981325View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

July 31, 2029

Conditions
Basal Cell Carcinoma (BCC)First Line Treatment
Interventions
DRUG

Cemiplimab

Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for up to 12 months (max. 17 cycles).

Trial Locations (5)

Unknown

NOT_YET_RECRUITING

Helios Klinikum Erfurt, Erfurt

RECRUITING

Universitätsklinikum Erlangen, Erlangen

RECRUITING

Universitätsklinikum Leipzig, Leipzig

RECRUITING

Johannes Wesling Klinikum, Minden

RECRUITING

Universitätsklinikum Tübingen, Tübingen

All Listed Sponsors
collaborator

Skin Cancer Center Minden, Department of Dermatology, Johannes-Wesling-Klinikum Minden

UNKNOWN

collaborator

Translational Skin Cancer Research, University Duisburg-Essen

UNKNOWN

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

NCT06981325 - Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients | Biotech Hunter | Biotech Hunter